RABIF
gene geneOn this page
Also known as mss4
Summary
RABIF (RAB interacting factor, HGNC:9797) is a protein-coding gene on chromosome 1q32.1, encoding Guanine nucleotide exchange factor MSS4 (P47224). Guanine-nucleotide-releasing protein that acts on members of the SEC4/YPT1/RAB subfamily. It is a selective cancer dependency (DepMap: 26.7% of cell lines).
This gene encodes a member of the SCE4/YPT1/RAB family of small GTP-binding proteins that are involved in the regulation of intracellular vesicular transport. This protein stimulates GTP-GDP exchange in SEC4, and to a lesser extent in YPT1 and RAB3A, and may play a general role in vesicular transport.
Source: NCBI Gene 5877 — RefSeq curated summary.
At a glance
- Clinical variants (ClinVar): 13 total
- Cancer dependency (DepMap): dependent in 26.7% of screened cell lines
- MANE Select transcript:
NM_002871
Identifiers
Gene identifiers
| Field | Value |
|---|---|
| HGNC ID | HGNC:9797 |
| Approved symbol | RABIF |
| Name | RAB interacting factor |
| Location | 1q32.1 |
| Locus type | gene with protein product |
| Status | Approved |
| Aliases | mss4 |
| Ensembl gene | ENSG00000183155 |
| Ensembl biotype | protein_coding |
| OMIM | 603417 |
| Entrez | 5877 |
Gene structure
Transcript identifiers
Ensembl transcripts: 2 — 2 protein_coding
ENST00000367262, ENST00000914087
RefSeq mRNA: 1 — MANE Select: NM_002871
NM_002871
CCDS: CCDS1428
Canonical transcript exons
ENST00000367262 — 2 exons
| Exon | Start | End |
|---|---|---|
| ENSE00001444003 | 202878282 | 202881223 |
| ENSE00001444005 | 202888973 | 202889149 |
Expression profiles
Bgee: expression breadth ubiquitous, 271 present calls, max score 94.75.
FANTOM5 (CAGE): breadth ubiquitous, TPM avg 27.5975 / max 150.7908, expressed in 1816 samples.
FANTOM5 promoters (6 alternative TSS)
| Promoter ID | TPM avg | Samples expressed |
|---|---|---|
| 16743 | 25.5019 | 1813 |
| 16744 | 0.9944 | 595 |
| 16745 | 0.3961 | 185 |
| 16746 | 0.3563 | 159 |
| 16742 | 0.2809 | 134 |
| 16747 | 0.0680 | 14 |
Top tissues by expression
287 total, by Bgee expression score (0-100, higher = more expressed):
| Tissue | Anatomy ID | Expression score | Quality |
|---|---|---|---|
| cervix squamous epithelium | UBERON:0006922 | 94.75 | gold quality |
| sperm | CL:0000019 | 93.20 | gold quality |
| tongue squamous epithelium | UBERON:0006919 | 92.12 | gold quality |
| male germ cell | CL:0000015 | 91.74 | silver quality |
| squamous epithelium | UBERON:0006914 | 88.43 | gold quality |
| hair follicle | UBERON:0002073 | 88.36 | gold quality |
| Brodmann (1909) area 10 | UBERON:0013541 | 88.31 | gold quality |
| cervix epithelium | UBERON:0004801 | 88.09 | silver quality |
| gingival epithelium | UBERON:0001949 | 87.61 | gold quality |
| epithelium of esophagus | UBERON:0001976 | 86.90 | gold quality |
| endothelial cell | CL:0000115 | 86.71 | gold quality |
| gingiva | UBERON:0001828 | 86.58 | gold quality |
| amniotic fluid | UBERON:0000173 | 86.38 | gold quality |
| esophagus squamous epithelium | UBERON:0006920 | 86.36 | gold quality |
| primordial germ cell in gonad | CL:0000670 ∩ UBERON:0000991 | 86.32 | gold quality |
| male germ line stem cell (sensu Vertebrata) in testis | CL:0000089 ∩ UBERON:0000473 | 86.04 | gold quality |
| epithelial cell of pancreas | CL:0000083 | 85.70 | silver quality |
| pancreatic ductal cell | CL:0002079 | 85.62 | gold quality |
| adult organism | UBERON:0007023 | 84.62 | gold quality |
| palpebral conjunctiva | UBERON:0001812 | 84.35 | gold quality |
| Brodmann (1909) area 46 | UBERON:0006483 | 84.30 | gold quality |
| left testis | UBERON:0004533 | 84.23 | gold quality |
| right testis | UBERON:0004534 | 84.22 | gold quality |
| secondary oocyte | CL:0000655 | 84.13 | gold quality |
| endometrium epithelium | UBERON:0004811 | 83.98 | gold quality |
| testis | UBERON:0000473 | 83.70 | gold quality |
| Brodmann (1909) area 23 | UBERON:0013554 | 83.57 | gold quality |
| epithelium of nasopharynx | UBERON:0001951 | 83.21 | gold quality |
| nasal cavity epithelium | UBERON:0005384 | 83.18 | gold quality |
| bone marrow | UBERON:0002371 | 82.69 | gold quality |
Single-cell (SCXA)
Detected in 1 experiment(s), a significant marker in 1.
| Experiment | Marker? | Max mean expression |
|---|---|---|
| E-ANND-3 | yes | 5.24 |
Regulation
Is transcription factor: no
Upstream regulators (CollecTRI, top): E2F4
miRNA regulators (miRDB)
97 targeting RABIF, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):
| miRNA | Max score | Avg score | miRNA target_count |
|---|---|---|---|
| HSA-MIR-3163 | 100.00 | 77.23 | 8605 |
| HSA-MIR-200B-3P | 100.00 | 73.31 | 2693 |
| HSA-MIR-200C-3P | 100.00 | 73.35 | 2685 |
| HSA-MIR-429 | 100.00 | 73.44 | 2698 |
| HSA-MIR-4283 | 100.00 | 66.42 | 2097 |
| HSA-MIR-513B-5P | 99.99 | 69.96 | 2150 |
| HSA-MIR-371B-5P | 99.99 | 75.34 | 4759 |
| HSA-MIR-186-5P | 99.99 | 70.83 | 3707 |
| HSA-MIR-4534 | 99.99 | 66.58 | 1907 |
| HSA-MIR-373-5P | 99.98 | 75.36 | 4753 |
| HSA-MIR-616-5P | 99.98 | 75.58 | 4775 |
| HSA-MIR-4487 | 99.96 | 64.58 | 1252 |
| HSA-MIR-96-5P | 99.95 | 72.80 | 2140 |
| HSA-MIR-12133 | 99.92 | 71.82 | 2006 |
| HSA-MIR-6508-5P | 99.92 | 70.67 | 2465 |
| HSA-MIR-5680 | 99.91 | 69.83 | 3421 |
| HSA-MIR-1271-5P | 99.91 | 71.99 | 1972 |
| HSA-MIR-3529-3P | 99.90 | 73.55 | 3045 |
| HSA-MIR-153-5P | 99.89 | 73.86 | 6317 |
| HSA-MIR-182-5P | 99.87 | 74.03 | 2589 |
| HSA-MIR-10395-5P | 99.86 | 67.35 | 676 |
| HSA-MIR-8067 | 99.86 | 69.59 | 2260 |
| HSA-MIR-3150A-3P | 99.76 | 64.44 | 1640 |
| HSA-MIR-6763-5P | 99.76 | 64.68 | 1767 |
| HSA-MIR-6505-5P | 99.73 | 69.25 | 1595 |
| HSA-MIR-3714 | 99.71 | 70.74 | 2671 |
| HSA-MIR-12124 | 99.68 | 69.17 | 2700 |
| HSA-MIR-5093 | 99.67 | 69.26 | 2291 |
| HSA-MIR-6762-3P | 99.66 | 66.94 | 1188 |
| HSA-MIR-4261 | 99.59 | 70.30 | 3415 |
Functional genomics
DepMap (CRISPR cell-line fitness): dependent in 26.7% of screened cell lines.
Literature-anchored findings (GeneRIF, showing 5)
- MSS4 modulates Rab15 activity in early endocytosis (PMID:12105226)
- The expression levels of cellular Mss4 mRNA and protein are rapidly changed in response to a broad range of extracellular stress stimuli. (PMID:22495352)
- The findings reveal a crucial role of RABIF in vesicle transport and establish RABIF as a Rab-stabilizing holdase chaperone, a previously unrecognized mode of Rab regulation independent of its GDP-releasing activity. (PMID:28894007)
- Identification of the Roles of Coagulation-related Signature and its Key Factor RABIF in Hepatoma Cell Malignancy. (PMID:37644748)
- RABIF promotes hepatocellular carcinoma progression through regulation of mitophagy and glycolysis. (PMID:39414994)
Cross-species orthologs
6 orthologs
| Organism | Symbol | Gene ID |
|---|---|---|
| danio_rerio | rabif | ENSDARG00000002690 |
| mus_musculus | Rabif | ENSMUSG00000042229 |
| rattus_norvegicus | Rabif | ENSRNOG00000004424 |
| rattus_norvegicus | LOC120100841 | ENSRNOG00000063309 |
| drosophila_melanogaster | strat | FBGN0032020 |
| caenorhabditis_elegans | WBGENE00014938 |
Protein
Protein identifiers
Guanine nucleotide exchange factor MSS4 — P47224 (reviewed: P47224)
Alternative names: Rab-interacting factor
All UniProt accessions (1): P47224
UniProt curated annotations — full annotation on UniProt →
Function. Guanine-nucleotide-releasing protein that acts on members of the SEC4/YPT1/RAB subfamily. Stimulates GDP release from both YPT1, RAB3A and RAB10, but is less active on these proteins than on the SEC4 protein. Might play a general role in vesicular transport.
Subunit / interactions. Interacts with RAB8A.
Tissue specificity. Ubiquitous.
Similarity. Belongs to the DSS4/MSS4 family.
RefSeq proteins (1): NP_002862* (*=MANE)
Domains & families (InterPro)
| ID | Name | Type |
|---|---|---|
| IPR007515 | Mss4 | Family |
| IPR011057 | Mss4-like_sf | Homologous_superfamily |
| IPR011323 | Mss4/transl-control_tumour | Homologous_superfamily |
Pfam: PF04421
UniProt features (23 total): strand 11, binding site 4, helix 2, turn 2, chain 1, domain 1, modified residue 1, sequence conflict 1
Structure
Experimental structures (PDB)
2 structures.
| PDB | Method | Resolution (Å) |
|---|---|---|
| 2FU5 | X-RAY DIFFRACTION | 2 |
| 1FWQ | SOLUTION NMR |
Predicted structure (AlphaFold)
| Model | pLDDT | Fraction very-high |
|---|---|---|
| AF-P47224-F1 | 89.85 | 0.78 |
Functional residue map
Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.
Ligand- & substrate-binding residues (4): 23; 26; 94; 97
Post-translational modifications (1): 1
Function
Pathways and Gene Ontology
Reactome pathways
0 pathways
MSigDB gene sets: 150 (showing top):
GSE45365_NK_CELL_VS_CD8_TCELL_UP, BUYTAERT_PHOTODYNAMIC_THERAPY_STRESS_DN, TGCGCANK_UNKNOWN, FISCHER_G1_S_CELL_CYCLE, GOBP_MEMBRANE_FUSION, GRAESSMANN_APOPTOSIS_BY_DOXORUBICIN_DN, GRAESSMANN_RESPONSE_TO_MC_AND_DOXORUBICIN_DN, THEILGAARD_NEUTROPHIL_AT_SKIN_WOUND_DN, GOBP_VESICLE_MEDIATED_TRANSPORT, MODULE_195, MODULE_301, ATTCTTT_MIR186, SCHLOSSER_SERUM_RESPONSE_DN, BOYAULT_LIVER_CANCER_SUBCLASS_G1_UP, STONER_ESOPHAGEAL_CARCINOGENESIS_DN
GO Biological Process (4): post-Golgi vesicle-mediated transport (GO:0006892), small GTPase-mediated signal transduction (GO:0007264), protein transport (GO:0015031), membrane fusion (GO:0061025)
GO Molecular Function (4): guanyl-nucleotide exchange factor activity (GO:0005085), zinc ion binding (GO:0008270), protein binding (GO:0005515), metal ion binding (GO:0046872)
GO Cellular Component (2): cytosol (GO:0005829), membrane (GO:0016020)
GO top-level categories
Rollup of top GO terms by namespace:
| Category | Terms |
|---|---|
| cellular anatomical structure | 2 |
| Golgi vesicle transport | 1 |
| intracellular signaling cassette | 1 |
| transport | 1 |
| intracellular protein localization | 1 |
| establishment of protein localization | 1 |
| membrane organization | 1 |
| GTP binding | 1 |
| GDP binding | 1 |
| GTPase regulator activity | 1 |
| transition metal ion binding | 1 |
| binding | 1 |
| cation binding | 1 |
| cytoplasm | 1 |
Protein interactions and networks
STRING
4302 interactions, top by confidence (×1000):
| Protein A | Protein B | Partner UniProt | Score |
|---|---|---|---|
| RABIF | GRB2 | P29354 | 995 |
| RABIF | SOS1 | Q07889 | 981 |
| RABIF | LCP2 | Q13094 | 978 |
| RABIF | CDC42 | P21181 | 971 |
| RABIF | SOS2 | Q07890 | 965 |
| RABIF | ARF1 | P10947 | 953 |
| RABIF | RHOA | P06749 | 945 |
| RABIF | MCF2 | P10911 | 935 |
| RABIF | TIAM1 | Q13009 | 933 |
| RABIF | RASA1 | P20936 | 930 |
| RABIF | RAB8A | P24407 | 927 |
| RABIF | RCC1 | P18754 | 927 |
| RABIF | AKT1 | P31749 | 924 |
| RABIF | NCK1 | P16333 | 917 |
| RABIF | CYTH1 | Q15438 | 913 |
IntAct
104 interactions, top by confidence:
| A | B | Type | Score |
|---|---|---|---|
| RABIF | RAB8A | psi-mi:“MI:0915”(physical association) | 0.850 |
| RAB8A | RABIF | psi-mi:“MI:0407”(direct interaction) | 0.850 |
| RABIF | RAB1B | psi-mi:“MI:0915”(physical association) | 0.800 |
| RABIF | RAB3A | psi-mi:“MI:0915”(physical association) | 0.780 |
| RAB3A | RABIF | psi-mi:“MI:0915”(physical association) | 0.780 |
| RABIF | RAB3A | psi-mi:“MI:0914”(association) | 0.780 |
| RABIF | RAB1A | psi-mi:“MI:0915”(physical association) | 0.670 |
| RAB1A | RABIF | psi-mi:“MI:0915”(physical association) | 0.670 |
| RAB3B | RABIF | psi-mi:“MI:0915”(physical association) | 0.670 |
| SNRPB | SART1 | psi-mi:“MI:0914”(association) | 0.640 |
| RAB8A | WDR91 | psi-mi:“MI:0914”(association) | 0.600 |
| TCF4 | RABIF | psi-mi:“MI:0915”(physical association) | 0.560 |
| REL | RABIF | psi-mi:“MI:0915”(physical association) | 0.560 |
| RASSF5 | RABIF | psi-mi:“MI:0915”(physical association) | 0.560 |
| RABIF | TCF4 | psi-mi:“MI:0915”(physical association) | 0.560 |
| RABIF | RASSF5 | psi-mi:“MI:0915”(physical association) | 0.560 |
| RABIF | LNX1 | psi-mi:“MI:0915”(physical association) | 0.560 |
| RABIF | LZTS1 | psi-mi:“MI:0915”(physical association) | 0.560 |
BioGRID (98): RABIF (Two-hybrid), REL (Two-hybrid), TCF4 (Two-hybrid), RASSF5 (Two-hybrid), AHSA1 (Co-fractionation), KIAA0368 (Co-fractionation), NARS (Co-fractionation), RABIF (Co-fractionation), RABIF (Co-fractionation), RABIF (Co-fractionation), RABIF (Co-fractionation), RABIF (Co-fractionation), RABIF (Co-fractionation), RABIF (Co-fractionation), RABIF (Co-fractionation)
ESM2 similar proteins: A1KXW8, A6QL50, E1BGQ2, H0Y354, O94955, P47224, Q08326, Q0IIH8, Q1JQA1, Q1RMS8, Q1RMZ1, Q2TBU5, Q3T1H6, Q4R372, Q4R528, Q4R9C4, Q5F480, Q5F4A1, Q5I0G3, Q5RCQ0, Q5RFG8, Q5TFE4, Q5TYM5, Q641X7, Q6L9T8, Q6PIP5, Q7L622, Q7Z6J8, Q7ZX59, Q86X60, Q8BFZ8, Q8BKW4, Q8BM85, Q8BX13, Q8CEL2, Q8N5C7, Q8N635, Q8NHU2, Q8TCF1, Q8TCJ0
Diamond homologs: O43057, P47224, Q08326, Q91X96, Q9VLP3, Q9U1X4
SIGNOR signaling
0 interactions.
Enriched among interaction partners
Reactome pathways and GO biological processes over-represented among this gene’s 54 IntAct physical interaction partners (hypergeometric vs the genome-wide background, BH-FDR, gene-set size 15–500, ranked by fold). A functional readout of the neighbourhood — distinct from this gene’s own memberships above, and biased toward well-studied / hub proteins, so read it as themes rather than proof.
Reactome pathways:
| Pathway | Partners | Fold | FDR |
|---|---|---|---|
| RAB geranylgeranylation | 12 | 48.3× | 2e-15 |
| RAB GEFs exchange GTP for GDP on RABs | 8 | 23.1× | 2e-07 |
GO biological processes:
| GO term | Partners | Fold | FDR |
|---|---|---|---|
| exocytosis | 9 | 26.8× | 1e-08 |
Disease & clinical
Clinical variants and AI predictions
ClinVar
13 variants total. Per-class counts are floors (≥ shown; pagination cap):
| Classification | Count (floor) |
|---|---|
| Pathogenic | 0 |
| Likely pathogenic | 0 |
| Uncertain significance | 6 |
| Likely benign | 0 |
| Benign | 1 |
Top pathogenic / likely-pathogenic (0)
SpliceAI
392 predictions. Top by Δscore:
| Variant | Effect | Δscore |
|---|---|---|
| 1:202888969:CTA:C | donor_loss | 1.0000 |
| 1:202888970:TACC:T | donor_loss | 1.0000 |
| 1:202888971:ACC:A | donor_loss | 1.0000 |
| 1:202888972:C:A | donor_loss | 1.0000 |
| 1:202880980:A:AC | donor_gain | 0.9900 |
| 1:202880981:C:CC | donor_gain | 0.9900 |
| 1:202881219:AAAAG:A | acceptor_gain | 0.9900 |
| 1:202881220:AAAG:A | acceptor_gain | 0.9900 |
| 1:202881221:AAG:A | acceptor_gain | 0.9900 |
| 1:202881222:AG:A | acceptor_gain | 0.9900 |
| 1:202881223:GC:G | acceptor_loss | 0.9900 |
| 1:202881224:C:CC | acceptor_gain | 0.9900 |
| 1:202881225:T:C | acceptor_loss | 0.9900 |
| 1:202888968:CCTA:C | donor_loss | 0.9900 |
| 1:202880985:T:C | donor_gain | 0.9800 |
| 1:202881229:G:C | acceptor_gain | 0.9800 |
| 1:202888328:T:TA | donor_gain | 0.9800 |
| 1:202888963:G:A | donor_gain | 0.9800 |
| 1:202889044:T:TA | donor_gain | 0.9800 |
| 1:202881228:A:T | acceptor_gain | 0.9700 |
| 1:202881229:G:GC | acceptor_gain | 0.9700 |
| 1:202888997:C:A | donor_gain | 0.9700 |
| 1:202889071:A:AC | donor_gain | 0.9700 |
| 1:202889072:C:CC | donor_gain | 0.9700 |
| 1:202880984:A:AC | donor_gain | 0.9600 |
| 1:202881227:C:CT | acceptor_gain | 0.9600 |
| 1:202888855:AAGG:A | donor_gain | 0.9600 |
| 1:202888972:CCTGT:C | donor_gain | 0.9600 |
| 1:202889004:TGCAG:T | donor_gain | 0.9600 |
| 1:202889072:CTCG:C | donor_gain | 0.9600 |
AlphaMissense
804 scored. Top likely-pathogenic:
| Variant | Protein change | am_pathogenicity |
|---|---|---|
| 1:202881042:C:T | G103D | 1.000 |
| 1:202881043:C:G | G103R | 1.000 |
| 1:202881048:G:T | P101Q | 1.000 |
| 1:202881069:C:T | C94Y | 1.000 |
| 1:202881070:A:G | C94R | 1.000 |
| 1:202881075:A:T | L92Q | 1.000 |
| 1:202881104:G:C | F82L | 1.000 |
| 1:202881104:G:T | F82L | 1.000 |
| 1:202881106:A:G | F82L | 1.000 |
| 1:202881145:A:G | W69R | 1.000 |
| 1:202881145:A:T | W69R | 1.000 |
| 1:202881006:A:T | V115E | 0.999 |
| 1:202881042:C:A | G103V | 0.999 |
| 1:202881045:A:T | I102N | 0.999 |
| 1:202881049:G:A | P101S | 0.999 |
| 1:202881051:C:T | G100E | 0.999 |
| 1:202881052:C:G | G100R | 0.999 |
| 1:202881052:C:T | G100R | 0.999 |
| 1:202881059:A:C | C97W | 0.999 |
| 1:202881060:C:A | C97F | 0.999 |
| 1:202881060:C:G | C97S | 0.999 |
| 1:202881060:C:T | C97Y | 0.999 |
| 1:202881061:A:G | C97R | 0.999 |
| 1:202881061:A:T | C97S | 0.999 |
| 1:202881066:G:T | A95E | 0.999 |
| 1:202881068:G:C | C94W | 0.999 |
| 1:202881069:C:A | C94F | 0.999 |
| 1:202881069:C:G | C94S | 0.999 |
| 1:202881070:A:T | C94S | 0.999 |
| 1:202881075:A:G | L92P | 0.999 |
dbSNP variants (sampled 300 via entrez): RS1000252518 (1:202889157 C>A,T), RS1000437732 (1:202883760 T>C), RS1000615324 (1:202880930 G>A,C), RS1001017950 (1:202888116 C>A), RS1001277277 (1:202877779 ATTC>A), RS1002574776 (1:202887656 C>A), RS1002708466 (1:202881729 G>A,T), RS1002711203 (1:202889719 A>C), RS1002791378 (1:202887825 A>G), RS1002927478 (1:202887488 G>A), RS1003184366 (1:202888036 T>C), RS1003753024 (1:202880087 A>T), RS1003808019 (1:202886573 A>T), RS1003887625 (1:202879448 T>C), RS1003902990 (1:202886270 G>A,C,T)
Disease associations
OMIM: gene MIM:603417 | disease phenotypes:
GenCC curated gene-disease
Mondo (0):
Orphanet (0):
HPO phenotypes
0 total (0 of 0 shown, HPO-id order):
GWAS associations
0 associations (top):
Drugs & pharmacology
Drug and pharmacology data
Is drug target: no
PharmGKB: 1 entry (VIP=true, CPIC=false)
CTD chemical–gene interactions
19 total (human), top 19 by PubMed support.
| Chemical | Actions (top 5) | PubMed papers |
|---|---|---|
| Benzo(a)pyrene | increases methylation, decreases expression | 2 |
| methylmercuric chloride | decreases expression | 1 |
| butyraldehyde | decreases expression | 1 |
| CGP 52608 | affects binding, increases reaction | 1 |
| abrine | decreases expression | 1 |
| (+)-JQ1 compound | increases expression | 1 |
| Leflunomide | decreases expression | 1 |
| Acetaminophen | increases expression | 1 |
| Vehicle Emissions | decreases expression | 1 |
| Diethylstilbestrol | decreases expression | 1 |
| Doxorubicin | decreases expression | 1 |
| Ivermectin | decreases expression | 1 |
| Nickel | increases expression | 1 |
| Smoke | decreases expression | 1 |
| Urethane | increases expression | 1 |
| Valproic Acid | decreases expression | 1 |
| Vincristine | decreases expression | 1 |
| Lactic Acid | decreases expression | 1 |
| Particulate Matter | decreases expression | 1 |
Clinical trials (associated diseases)
0 trials via MONDO — disease-level, not drug-specific.
Related Atlas pages
No linked Atlas pages yet — the cross-entity mesh grows as the corpus expands.